The neutrophil, not the tumor - Serum CA 15-3 elevation as a result of granulocyte - Colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy

被引:17
作者
Pentheroudakis, G
Malamou-Mitsi, V
Briasoulis, E
Damala, K
Vassou, A
Vartholomatos, G
Kolaitis, N
Pavlidis, N
机构
[1] Ioannina Univ Hosp, Dept Med Oncol, Ioannina 45110, Greece
[2] Ioannina Univ Hosp, Dept Pathol, Ioannina 45110, Greece
[3] Ioannina Univ Hosp, Dept Hematol, Ioannina 45110, Greece
[4] Ioannina Univ Hosp, Haematol Lab, Mol Biol Unit, Ioannina 45110, Greece
[5] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece
关键词
CA; 15-3; MUC1; breast carcinoma; chemotherapy; granulocyte-colony-stimulating factor (G-CSF);
D O I
10.1002/cncr.20581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated the role of G-CSF-induced neutrophil MUC1 expression in this setting. Methods. Twenty-two patients with resected early breast carcinoma and 6 patients with high-grade lymphoma received chemotherapy cycles with or without G-CSF Support. When given, G-CSF was administered for either 5 or 10 days per cycle. Immunocytochemical staining and flow cytometric analysis of peripheral blood neutrophils and bone marrow myeloid cells for MUC1 epitopes were performed during treatment. Results. At baseline, the median serum CA 15-3 was 16 U/mL, with weak MUC1 expression in peripheral neutrophils (median immunocytochemical score [ICCS]=40, flow cytometric score [FCS]=211 antibody molecules per neutrophil). For patients receiving chemotherapy cycles with 5-day G-CSF support, median CA 15-3 levels increased moderately (median=28 U/mL; P=0.016) and absolute neutrophil counts (ANC) did not increase, whereas ICC staining showed a moderate increase (median ICCS=105; P=0.015). For patients receiving chemotherapy cycles with 10-day G-CSF, serum CA 15-3 levels increased 2-4-fold from baseline levels and reached abnormal levels (median=47; P<0.0005) and the ANC increased (median=21,400/mm(3); P=0.007), whereas significant induction of MUC1 expression occurred in the cell membrane and mostly in the cytoplasm of neutrophils (median ICCS=162; P=0.001). Flow cytometry detected increased cytoplasmic, but not surface, neutrophil MUC1 expression in the 10-day G-CSF group only (baseline median FCS=3975, 4th cycle median=6327 molecules per cell; P=0.028). In the bone marrow, induction of MUC1 expression was observed in the 10-day G-CSF group only in band forms and neutrophils, but not in more immature myeloid cells. Serum CA 15-3 levels and ICC score were found to demonstrate a linear relation. When ICCS and ANC were incorporated in a combined score, its relation with serum CA 15-3 levels demonstrated a parabolic (cubic) pattern. Serum CA 15-3 levels, ANC, and neutrophil MUC1 staining returned to baseline after the completion of therapy. No excess of malignant recurrences were observed. Conclusions. Women with resected breast carcinoma who received G-CSF-primed chemotherapy showed serum CA 15-3 elevation due to an increase in peripheral blood neutrophil number and induced neutrophil cytoplasmic MUC1 expression, which was caused by G-CSF. Physicians should be aware of this interaction.
引用
收藏
页码:1767 / 1775
页数:9
相关论文
共 23 条
[1]   Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer.: Comparison of CK19, MUC1 and CEA using RT-PCR [J].
Berois, N ;
Varangot, M ;
Aizen, B ;
Estrugo, R ;
Zarantonelli, L ;
Fernández, P ;
Krygier, G ;
Simonet, F ;
Barrios, E ;
Musé, L ;
Osinaga, E .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (06) :717-723
[2]  
Briasoulis E, 2001, CANCER, V91, P909, DOI 10.1002/1097-0142(20010301)91:5<909::AID-CNCR1080>3.0.CO
[3]  
2-X
[4]   Expression of MUC-1 epitopes on normal bone marrow:: Implications for the detection of micrometastatic tumor cells [J].
Brugger, W ;
Bühring, HJ ;
Grünebach, F ;
Vogel, W ;
Kaul, S ;
Müller, R ;
Brümmendorf, TH ;
Ziegler, BL ;
Rappold, I ;
Brossart, P ;
Scheding, S ;
Kanz, L .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1535-1544
[5]  
BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155
[6]   Granulocyte colony-stimulating factor is present in human milk and its receptor is present in human fetal intestine [J].
Calhoun, DA ;
Lunoe, M ;
Du, Y ;
Christensen, RD .
PEDIATRICS, 2000, 105 (01) :107
[7]   Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues [J].
Cao, Y ;
Karsten, U ;
Hilgers, J .
TUMOR BIOLOGY, 1998, 19 :88-99
[8]   Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].
Citron, ML ;
Berry, DA ;
Cirrincione, C ;
Hudis, C ;
Winer, EP ;
Gradishar, WJ ;
Davidson, NE ;
Martino, S ;
Livingston, R ;
Ingle, JN ;
Perez, EA ;
Carpenter, J ;
Hurd, D ;
Holland, JF ;
Smith, BL ;
Sartor, CI ;
Leung, EH ;
Abrams, J ;
Schilsky, RL ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439
[9]   CIRCULATING CA 15-3 LEVELS IN THE POSTSURGICAL FOLLOW-UP OF BREAST-CANCER PATIENTS AND IN NON-MALIGNANT DISEASES [J].
COLOMER, R ;
RUIBAL, A ;
GENOLLA, J ;
RUBIO, D ;
DELCAMPO, JM ;
BODI, R ;
SALVADOR, L .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (02) :123-133
[10]   DETECTION OF ISOLATED MAMMARY-CARCINOMA CELLS IN MARROW OF PATIENTS WITH PRIMARY BREAST-CANCER [J].
DEARNALEY, DP ;
SLOANE, JP ;
IMRIE, S ;
COOMBES, RC ;
ORMEROD, MG ;
LUMLEY, H ;
JONES, M ;
NEVILLE, AM .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1983, 76 (05) :359-364